Inhibikase Q2 net loss $9.9M; Phase 2b IKT-001 PAH trial to start H2 2025

Inhibikase Therapeutics, Inc.

2025-Q2 EPS reported -$0.26 vs consensus -$0.09 ▼ miss (-186.0%)

Cash and marketable securities $87.7M at June 30, 2025, vs $97.5M at Dec 31, 2024.
Net loss $9.9M ($0.11/share) for Q2 2025 vs $5.0M ($0.66/share) in Q2 2024.
R&D expenses $5.3M in Q2 2025, up from $3.1M in Q2 2024; SG&A $5.9M vs $2.0M.
Phase 2b IMPROVE-PAH study of IKT-001 (prodrug of imatinib) to begin H2 2025.
Primary endpoint: change in pulmonary vascular resistance at Week 26; secondary include 6MWD.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.